A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Completed · Phase 2 · Has a placebo group

Conditions studied: Geographic Atrophy

In brief

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

Key facts

Study ID

NCT05811351

Run by

Janssen Research & Development, LLC

People needed

305

Starts

2023-03-06

Expected to finish

2026-02-23

Last updated by the study team

2026-03-13

Who can join

Age: 60 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have non-subfoveal (defined as not involving the center point of the fovea) geographic atrophy (GA) secondary to age-related macular degeneration (AMD) with an area that can be measured and measures 2.5 millimeter square (mm\^2) to 17.5 mm\^2 (1- and 7- disc areas respectively), determined by the central reading center (CRC) from screening images of fundus autofluorescence (FAF) and spectral domain optical coherence tomography (SD-OCT)
• If GA is multifocal, at least one focal lesion must be greater than or equal to (>=) 1.25 mm\^2 (0.5- disc area), as assessed by the CRC
• GA can be photographed in its entirety by FAF, using a 30- degree image centered on the fovea, as assessed by the CRC
• Fellow eye must be present with a best corrected distance visual acuity (BCVA) of counting fingers or better
• Man or woman (according to their reproductive organs and functions assigned by chromosomal complement)

You may not qualify if…

• History of transpupillary thermotherapy, photodynamic therapy or external-beam radiation therapy in the region of study eye
• Any prior thermal laser in the macular region, regardless of indication
• History of retinal detachment (with or without repair)
• Active, infectious conjunctivitis, keratitis, scleritis, or endophthalmitis
• Any sign of diabetic retinopathy or central serous chorioretinopathy

Where it is running

• Oftalmika — Bydgoszcz, Poland
• Uno Med — Tarnów, Poland
• Retina Consultants of Southern California — Redlands, California, United States
• Retinal Research Institute — Phoenix, Arizona, United States
• Retina Associates Southwest PC — Tucson, Arizona, United States
• Retina Consultants of Orange County — Fullerton, California, United States
• Retina Associates Of Southern California — Huntington Beach, California, United States
• Shiley Eye Institute Jacobs Retina Center — La Jolla, California, United States
• Jules Stein Eye Institute UCLA — Los Angeles, California, United States
• The Retina Partners — Los Angeles, California, United States
• California Retina Consultants — Oxnard, California, United States
• Stanford Health Care — Palo Alto, California, United States
• California Eye Medical Specialists — Pasadena, California, United States
• Retina Consultants San Diego — Poway, California, United States
• Bay Area Retina Associates — Walnut Creek, California, United States
• Colorado Retina - Lakewood Clinic — Lakewood, Colorado, United States
• Retina Group of Florida — Fort Lauderdale, Florida, United States
• National Opthalmic Research Institute — Fort Myers, Florida, United States
• VitreoRetinal Associates, PA — Gainesville, Florida, United States
• MedEye Associates — Miami, Florida, United States
• Retina Specialty Institute — Pensacola, Florida, United States
• Fort Lauderdale Eye Institute — Plantation, Florida, United States
• Retina Vitreous Associates of Florida — St. Petersburg, Florida, United States
• East Florida Eye Institute — Stuart, Florida, United States
• Oculomedica — Bydgoszcz, Poland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.